CD22 and acute myeloid leukemia: This approach was compared with a previously validated anti-CD19/CD22 tandem CAR therapy, demonstrating that STAb-T cells exhibited an enhanced and faster in vitro cytotoxic activity.408 Given its ability to recruit bystander T cells, this innovative therapy is particularly promising for aggressive diseases prone to relapse with low effector T cells counts, such as AML.